Value through Innovation27 July 2016

Clinical Study Results

  • BUSCOPAN ® - Intestinal Diseases
    Clinical Study Number 202.848
    Study Indication Intestinal Diseases
    Product BUSCOPAN ®
    Generic Name Hyoscine butylbromide
    Lab Code
    Clinical Phase III
    Study Title

    A randomised, double-blind, independent 3rd party unblind, active-controlled, parallel-group, multi-centre trial, in contrast with anisodamine (654-II), 10 mg, to evaluate the efficacy and safety of Buscopan® solution for injection, 20 mg (intramuscularly) for the treatment of acute gastric or intestinal spasm-like pain

    Study Document Trial synopsis 202.848 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.